Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Ametek to acquire Paragon Medical in $1.9 billion cash deal

EditorPollock Mondal
Published 10/31/2023, 09:35 AM
© Reuters.

AMETEK, Inc. (NYSE: AME), a global industrial technology solutions firm, has announced its plans to acquire Paragon Medical from affiliates of American Securities LLC for an estimated $1.9 billion in cash, significantly expanding its medical-technology portfolio. This announcement furthers AMETEK's strategic growth model.

Paragon Medical is a Pierceton, Indiana-based company specializing in medical components and instruments for various surgical procedures such as orthopedics, minimally invasive surgery, robotic surgery, and drug delivery systems. The company's offerings include single-use surgical instruments and implantable components sold to top medical device manufacturers.

The acquisition is expected to considerably boost AMETEK's presence in the MedTech industry while opening up geographic and customer expansion opportunities as well as access to high-growth market segments. "This deal aligns with the AMETEK Growth Model, focusing on operational excellence, new product development, global and market expansion, strategic acquisitions, cash generation, and capital deployment," said David A. Zapico, AMETEK's Chairman and CEO.

Paragon Medical's annual sales reach approximately $500 million. This addition will complement AMETEK's existing medical businesses that reported $4.87 billion in sales during the first nine months of 2023.

In addition to this acquisition, Berwyn, Pa.-based AMETEK also purchased Amplifier Research, a company specializing in amplifiers and electromagnetic compatibility testing equipment with an annual turnover of $60 million.

The transaction with Paragon Medical is subject to customary closing conditions and regulatory approvals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.